New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
Danese, S
New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? [electronic resource] - Gastroenterologie clinique et biologique Jun 2009 - S217-27 p. digital
Publication Type: Journal Article; Review
0399-8320
10.1016/S0399-8320(09)73157-4 doi
Anti-Inflammatory Agents--pharmacology
Antibodies, Monoclonal--pharmacology
Biological Products--therapeutic use
Clinical Trials as Topic
Colitis, Ulcerative--therapy
Crohn Disease--therapy
Drug Therapy, Combination
Humans
Inflammatory Bowel Diseases--drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha--antagonists & inhibitors
New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? [electronic resource] - Gastroenterologie clinique et biologique Jun 2009 - S217-27 p. digital
Publication Type: Journal Article; Review
0399-8320
10.1016/S0399-8320(09)73157-4 doi
Anti-Inflammatory Agents--pharmacology
Antibodies, Monoclonal--pharmacology
Biological Products--therapeutic use
Clinical Trials as Topic
Colitis, Ulcerative--therapy
Crohn Disease--therapy
Drug Therapy, Combination
Humans
Inflammatory Bowel Diseases--drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha--antagonists & inhibitors